Skip to Content
Upcoming Webinar

A Combination Treatment for Patients with Advanced Renal Cell Carcinoma

Date: January 29, 2026 | 2:00 PM

Date: Thursday, January 29 | 2 p.m. EST
Presenter: Brittney Carden, PharmD | USA Health Mitchell Cancer Institute

Cabozantinib (CABOMETYX®) + nivolumab (OPDIVO®) is a first-line option in advanced renal cell carcinoma, but the practical questions show up fast: what the data supports, what to watch for early, and how to manage adverse reactions without losing momentum on treatment.

This session will cover:

  • Key information on the use of cabozantinib + nivolumab in first-line advanced RCC (aRCC)
  • Efficacy and safety data for cabozantinib + nivolumab in first-line aRCC
  • Monitoring and management of select adverse reactions with cabozantinib monotherapy and cabozantinib + nivolumab (including considerations for OPDIVO Qvantig™ [nivolumab and hyaluronidase-nvhy])
  • Resources available to providers, patients, and caregivers

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.